Literature DB >> 15944290

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

Ralph A Willemsen1, Cees Ronteltap, Patrick Chames, Reno Debets, Reinder L H Bolhuis.   

Abstract

T cells require both primary and costimulatory signals for optimal activation. The primary Ag-specific signal is delivered by engagement of the TCR. The second Ag-independent costimulatory signal is mediated by engagement of the T cell surface costimulatory molecule CD28 with its target cell ligand B7. However, many tumor cells do not express these costimulatory molecules. We previously constructed phage display derived F(AB), G8, and Hyb3, Ab-based receptors with identical specificity but distinct affinities for HLA-A1/MAGE-A1, i.e., "TCR-like" specificity. These chimeric receptors comprised the FcepsilonRI-gamma signaling element. We analyzed whether linking the CD28 costimulation structure to it (gamma + CD28) could affect the levels of MHC-restricted cytolysis and/or cytokine production. Human scFv-G8(POS) T lymphocytes comprising the gamma + CD28 vs the gamma signaling element alone produced substantially more IL-2, TNF-alpha, and IFN-gamma in response to HLA-A1/MAGE-A1(POS) melanoma cells. Also a drastic increase in cytolytic capacity of scFv-G8(POS) T cells, equipped with gamma + CD28 vs the gamma-chain alone was observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944290     DOI: 10.4049/jimmunol.174.12.7853

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Authors:  B Altvater; S Pscherer; S Landmeier; V Niggemeier; H Juergens; J Vormoor; C Rossig
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 2.  How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Authors:  Albert T Gacerez; Benjamine Arellano; Charles L Sentman
Journal:  J Cell Physiol       Date:  2016-06-02       Impact factor: 6.384

Review 3.  Optimizing tumor immune response through combination of radiation and immunotherapy.

Authors:  Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan
Journal:  Med Oncol       Date:  2017-08-21       Impact factor: 3.064

Review 4.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 5.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Advances in immunotherapy for melanoma management.

Authors:  Mohammed Dany; Rose Nganga; Alissar Chidiac; Edith Hanna; Sara Matar; Dirk Elston
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

Review 7.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

9.  Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation.

Authors:  Peter C R Emtage; Agnes S Y Lo; Erica M Gomes; David L Liu; Rosa M Gonzalo-Daganzo; Richard P Junghans
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 10.  Immunotherapy of human cancers using gene modified T lymphocytes.

Authors:  Juan F Vera; Malcolm K Brenner; Gianpietro Dotti
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.